Field Evaluation of the Interferon Gamma Assay for Diagnosis of Tuberculosis in Water Buffalo ( Bubalus bubalis) Comparing Four Interpretative Criteria

Field Evaluation of the Interferon Gamma Assay for Diagnosis of Tuberculosis in Water Buffalo ( Bubalus bubalis) Comparing Four Interpretative Criteria

Bovine tuberculosis (BTB) is a world zoonosis that affects many species of domestic and wild animals. Mycobatherium Bovis is the leading cause of Buffalo water infection (Bubalus bubalis) and cattle and is a great concern for human health and for Buffalo producers in Italy. The BTB eradication program is based on the oversight of the slaughterhouse and intradermal skin tests. Other in vivo diagnostic methods such as interferon-gamma dosage (IFN-γ) have been developed and are widely used in cattle to accelerate the elimination of BTB positive animals. This study is the first to evaluate the use and performance of IFN-γ analyzes, which is used as a BTB diagnostic auxiliary test in Buffalo water and presents the results of an assessment on the 2012 test. at 2019 during the BTB Buffalo eradication program in Italy.

The study involved 489 buffaloes with a positive result for the unique intradermal tuberculin test (SITT). IFN-γ tests and unique intradermal comparative tuberculin test have been used as confirmation tests. Then, a total of 458 buffaloes, high on officially tuberculosis (OTF) flocks, which have been confirmed without BTB for at least 6 years have been subjected to IFN-γ tests. In addition, to evaluate the IFN-γ test in an OTF herd with a paratuberculosis infection (PTB), 103 buffaloes have been subjected simultaneously to sitit and IFN-γ tests.

Our results have shown that the IFN-γ test in buffalo species could reach high sensitivity values ​​and specificity, and that the level of sensitivity and specificity could be chosen on the basis of the interpretative criterion and antigens used in use. the state of health of the flock and the epidemiological context of the territory. The IFN-γ test and the use of different interpretation criteria have been useful for implementing BTB diagnostic strategies in Buffalo herds, with the possibility of a flexible use of the test.

 

Intracerebroceric administration of interferon-alpha has induced depressive behaviors and neurotransmitter changes in rhesus monkeys

Interferon-Alpha (IFN-α) is a widely used cytokine in the treatment of brain cancers and viral infections with side effects, including depression. Monoamine neurotransmitter systems have been found in important roles in the depression induced by the peripheral IFN, but how the peripheral IFN-α accesses the central nervous system and contributes to the development of depression is poorly known. This study was intended to develop a non-human primate model using IFN-α intracerebroventricular administration (5 days / week for 6 weeks) to observe induced depressive type behaviors and explore Contributions from monoamine neurotransmitter systems in the development of depression. In monkeys receiving I.C.V.

The IFN-α administration, Anhédonie has been observed as a decrease in sucrose consumption, as well as symptoms resembling depressives, including increased dumbbell behaviors, a decrease in spontaneous and reactive locomotion in the cage. Home, as well as the reduction of the exploration and an increased immobile in the Open field. Central IFN-α-chronic infusion significantly increased the concentrations of cerebrospinal fluid (CSF) of noredrenaline (Na) and 3,4-dihydroxyphenylacetic acid (DOPAC), but not 5-hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA). These metabolites of monoamine CSF showed associations with specific behaviors related to depression.

In conclusion, the IFN-α central administration caused an anhedonia and the behaviors related to depression comparable to the results with the peripheral administration, and the development of depression was associated with the malfunction of monoamine neurotransmitters.

 Field Evaluation of the Interferon Gamma Assay for Diagnosis of Tuberculosis in Water Buffalo ( Bubalus bubalis) Comparing Four Interpretative Criteria
Field Evaluation of the Interferon Gamma Assay for Diagnosis of Tuberculosis in Water Buffalo ( Bubalus bubalis) Comparing Four Interpretative Criteria

 

Type I interferon acts as a major obstacle to the establishment of persistent infectious infectious disease infections (IBDV)

An infectious scholarship disease virus (IBDV), the best famous member of the Birnaviridae family is a very relevant avian pathogen, which causes acute and persistent infections in different avian hosts. Here we describe the establishment of clonal, long-term and productive IBDV infections in DF-1 chicken embryonic fibroblasts. Although the returns of the virus in persistently infected cells are extremely lower than those detected in extremely infected cells, the form of the replication of isolated viruses of infected cells persistently is greater than that of the parental virus.

The DF-1 and IBDV cell lines persistently and infected are derived from them not responding to the I interferon (IFN) key. The sequencing of high speed genome has revealed that this defect is due to mutations affecting the IFNα / β 2 receptor subunit (IFNAR2) gene resulting from the expression of IFNAR2 polypeptides hosting large C-terminal terminal deletions that abolish the signaling capacity of the IFNα / β receiver complex. The ectopic expression of a recombinant chicken gene IFNAR2 effectively saves the reactivity of IFNα. Curriculated Cellular Lines IBDV derived from infected persistent cells have a considerably improved susceptibility in order to establish new IBDV persistent infections. In addition, experiments carried out with human hela cells devoid of the IFNAR2 gene completely summarize the results obtained with DF-1 cells, having a very improved capacity to survive the acute AIBDV infection phase and to support the establishment of Persistent IBDV infections.

Tissue, Total RNA, Human Tumor Cell Line, Hela (Cervix Adenocarcinoma), BioGenomics

MBS638661-005mg 0.05mg
EUR 485

Tissue, Total RNA, Human Tumor Cell Line, Hela (Cervix Adenocarcinoma), BioGenomics

MBS638661-5x005mg 5x0.05mg
EUR 1960

Total Protein - Human Tumor Cell Line: A431

P1255801 1 mg
EUR 216

Total Protein - Human Tumor Cell Line: Raji

P1255840 1 mg
EUR 216

Total Protein - Human Tumor Cell Line: Jurkat

P1255815 1 mg
EUR 216

Total Protein - Human Tumor Cell Line: K 562

P1255820 1 mg
EUR 216

Total Protein - Murine Embryonic Stem Cell Line D3

CBA-305 500 ?g
EUR 414
Description:
  • Isolated from mouse ES-D3 cell line
  • Presented as 500 µg at 1 mg/mL in NP-40 Solubilization Buffer

Total Protein - Human Tumor Cell Line: MCF 7

P1255830 1 mg
EUR 216

Membrane Protein - Human Tumor Cell Line: Hela

P3255811 0.1 mg
EUR 311

HeLa/GFP Cell Line

AKR-213 1 vial
EUR 460

HeLa/Cas9 Cell Line

AKR-5111 1 vial
EUR 460

cDNA - Human Tumor Cell Line: Hela

C1255811 40 reactions
EUR 424

Tissue, Total Protein, Human Tumor Cell Line, Jurkat (Human Acute T cell Leukemia)

MBS656972-1mg 1mg
EUR 565

Tissue, Total Protein, Human Tumor Cell Line, Jurkat (Human Acute T cell Leukemia)

MBS656972-5x1mg 5x1mg
EUR 2315

Tissue, Total Protein, Human Tumor Cell Line, A431 (Human Epidermoid Carcinoma)

MBS657363-1mg 1mg
EUR 565

Tissue, Total Protein, Human Tumor Cell Line, A431 (Human Epidermoid Carcinoma)

MBS657363-5x1mg 5x1mg
EUR 2315

Tissue, Total Protein, Human Tumor Cell Line, Raji (Human Lymphoma; B Lymphoma)

MBS657156-1mg 1mg
EUR 565

Tissue, Total Protein, Human Tumor Cell Line, Raji (Human Lymphoma; B Lymphoma)

MBS657156-5x1mg 5x1mg
EUR 2315

Total RNA - Human Tumor Cell Line: A431

R1255801-50 50 ug
EUR 229

Total RNA - Human Tumor Cell Line: Raji

R1255840-50 50 ug
EUR 229

Tissue, Total Protein, Human Tumor Cell Line, MCF 7 (Human Breast Adenocarcinima)

MBS657022-1mg 1mg
EUR 565

Tissue, Total Protein, Human Tumor Cell Line, MCF 7 (Human Breast Adenocarcinima)

MBS657022-5x1mg 5x1mg
EUR 2315

Genomic DNA - Human Tumor Cell Line: Hela

D1255811 100 ug
EUR 282

Total RNA - Human Tumor Cell Line: Jurkat

R1255815-50 50 ug
EUR 229

Total RNA - Human Tumor Cell Line: K 562

R1255820-50 50 ug
EUR 229

Tissue, Membrane Protein, Human Tumor Cell Line, Hela (Cervix Adenocarcinoma)

MBS639938-01mg 0.1mg
EUR 570

Tissue, Membrane Protein, Human Tumor Cell Line, Hela (Cervix Adenocarcinoma)

MBS639938-5x01mg 5x0.1mg
EUR 2345

Total RNA - Human Tumor Cell Line: MCF 7

R1255830-50 50 ug
EUR 229

Tissue, Total Protein, Human Tumor Cell Line, K 562 (Human Chronic Myelogenous Leukemia; Bone Marrow)

MBS657056-1mg 1mg
EUR 565

Tissue, Total Protein, Human Tumor Cell Line, K 562 (Human Chronic Myelogenous Leukemia; Bone Marrow)

MBS657056-5x1mg 5x1mg
EUR 2315

Tissue, Total RNA, Human Tumor Cell Line, Jurkat (Human Acute T cell Leukemia), BioGenomics

MBS638685-005mg 0.05mg
EUR 485

Tissue, Total RNA, Human Tumor Cell Line, Jurkat (Human Acute T cell Leukemia), BioGenomics

MBS638685-5x005mg 5x0.05mg
EUR 1960

Tissue, Total RNA, Human Tumor Cell Line, A431 (Human Epidermoid Carcinoma), BioGenomics

MBS638667-005mg 0.05mg
EUR 485

Tissue, Total RNA, Human Tumor Cell Line, A431 (Human Epidermoid Carcinoma), BioGenomics

MBS638667-5x005mg 5x0.05mg
EUR 1960

Tissue, Genomic DNA, Human Tumor Cell Line, Hela (Cervix Adenocarcinoma), BioGenomics

MBS654382-01mg 0.1mg
EUR 540

Tissue, Genomic DNA, Human Tumor Cell Line, Hela (Cervix Adenocarcinoma), BioGenomics

MBS654382-5x01mg 5x0.1mg
EUR 2275

Tissue, Total RNA, Human Tumor Cell Line, Raji (Human Lymphoma; B Lymphoma), BioGenomics

MBS638707-005mg 0.05mg
EUR 485

Tissue, Total RNA, Human Tumor Cell Line, Raji (Human Lymphoma; B Lymphoma), BioGenomics

MBS638707-5x005mg 5x0.05mg
EUR 1960

Tissue, Total RNA, Human Tumor Cell Line, MCF 7 (Human Breast Adenocarcinoma), BioGenomics

MBS638573-005mg 0.05mg
EUR 485

Tissue, Total RNA, Human Tumor Cell Line, MCF 7 (Human Breast Adenocarcinoma), BioGenomics

MBS638573-5x005mg 5x0.05mg
EUR 1960

Tissue cDNA, First Strand, Human Tumor Cell Line, Hela (Cervix Adenocarcinoma), BioGenomics

MBS652442-40Tests 40Tests
EUR 680

Tissue cDNA, First Strand, Human Tumor Cell Line, Hela (Cervix Adenocarcinoma), BioGenomics

MBS652442-5x40Tests 5x40Tests
EUR 2835

Total Protein - Human Tumor Tissue: Bone

P1235023 1 mg
EUR 542

Total Protein - Human Tumor Tissue: Lung

P1235152 1 mg
EUR 357

Total Protein - Human Tumor Tissue: Nose

P1235178 1 mg
EUR 542

Total Protein - Human Tumor Tissue: Skin

P1235218 1 mg
EUR 357

Tissue, Total Protein, Human Tumor, Nose

MBS657148-1mg 1mg
EUR 820

Tissue, Total Protein, Human Tumor, Nose

MBS657148-5x1mg 5x1mg
EUR 3470

Tissue, Total Protein, Human Tumor, Lung

MBS657223-1mg 1mg
EUR 680

Tissue, Total Protein, Human Tumor, Lung

MBS657223-5x1mg 5x1mg
EUR 2835

Tissue, Total Protein, Human Tumor, Skin

MBS657502-1mg 1mg
EUR 680

Tissue, Total Protein, Human Tumor, Skin

MBS657502-5x1mg 5x1mg
EUR 2835

Tissue, Total Protein, Human Tumor, Bone

MBS657551-1mg 1mg
EUR 820

Tissue, Total Protein, Human Tumor, Bone

MBS657551-5x1mg 5x1mg
EUR 3470

Total Protein - Human Tumor Tissue: Brain

P1235035 1 mg
EUR 542

Total Protein - Human Tumor Tissue: Colon

P1235090 1 mg
EUR 357

Total Protein - Human Tumor Tissue: Liver

P1235149 1 mg
EUR 357

Total Protein - Human Tumor Tissue: Ovary

P1235183 1 mg
EUR 357

Tissue, Total Protein, Human Tumor, Brain

MBS656992-1mg 1mg
EUR 820

Tissue, Total Protein, Human Tumor, Brain

MBS656992-5x1mg 5x1mg
EUR 3470

Tissue, Total Protein, Human Tumor, Ovary

MBS657111-05mg 0.5mg
EUR 595

Tissue, Total Protein, Human Tumor, Ovary

MBS657111-1mg 1mg
EUR 680

Tissue, Total Protein, Human Tumor, Ovary

MBS657111-5x1mg 5x1mg
EUR 2835

Tissue, Total Protein, Human Tumor, Colon

MBS657291-1mg 1mg
EUR 680

Tissue, Total Protein, Human Tumor, Colon

MBS657291-5x1mg 5x1mg
EUR 2835

Tissue, Total Protein, Human Tumor, Liver

MBS657316-1mg 1mg
EUR 680

Tissue, Total Protein, Human Tumor, Liver

MBS657316-5x1mg 5x1mg
EUR 2835

Total Protein - Human Tumor Tissue: Breast

P1235086 1 mg
EUR 357

Total Protein - Human Tumor Tissue: Kidney

P1235142 1 mg
EUR 357

Total Protein - Human Tumor Tissue: Oschea

P1235182 1 mg
EUR 542

Total Protein - Human Tumor Tissue: Rectum

P1235206 1 mg
EUR 357

Total Protein - Human Tumor Tissue: Spleen

P1235246 1 mg
EUR 357

Total Protein - Human Tumor Tissue: Testis

P1235260 1 mg
EUR 357

Total Protein - Human Tumor Tissue: Thymus

P1235264 1 mg
EUR 357

Total Protein - Human Tumor Tissue: Tonsil

P1235268 1 mg
EUR 542

Total Protein - Human Tumor Tissue: Ureter

P1235273 1 mg
EUR 542

Total Protein - Human Tumor Tissue: Uterus

P1235274 1 mg
EUR 357

Tissue, Total Protein, Human Tumor, Oschea

MBS656965-1mg 1mg
EUR 820

Tissue, Total Protein, Human Tumor, Oschea

MBS656965-5x1mg 5x1mg
EUR 3470

Tissue, Total Protein, Human Tumor, Rectum

MBS657089-1mg 1mg
EUR 680

Tissue, Total Protein, Human Tumor, Rectum

MBS657089-5x1mg 5x1mg
EUR 2835

Tissue, Total Protein, Human Tumor, Ureter

MBS657174-1mg 1mg
EUR 820

Tissue, Total Protein, Human Tumor, Ureter

MBS657174-5x1mg 5x1mg
EUR 3470

Tissue, Total Protein, Human Tumor, Breast

MBS657270-1mg 1mg
EUR 680

Tissue, Total Protein, Human Tumor, Breast

MBS657270-5x1mg 5x1mg
EUR 2835

Tissue, Total Protein, Human Tumor, Uterus

MBS657307-1mg 1mg
EUR 680

Tissue, Total Protein, Human Tumor, Uterus

MBS657307-5x1mg 5x1mg
EUR 2835

Tissue, Total Protein, Human Tumor, Spleen

MBS657312-1mg 1mg
EUR 680

Tissue, Total Protein, Human Tumor, Spleen

MBS657312-5x1mg 5x1mg
EUR 2835

Tissue, Total Protein, Human Tumor, Tonsil

MBS657353-1mg 1mg
EUR 820

Tissue, Total Protein, Human Tumor, Tonsil

MBS657353-5x1mg 5x1mg
EUR 3470

Tissue, Total Protein, Human Tumor, Testis

MBS657371-1mg 1mg
EUR 680

Tissue, Total Protein, Human Tumor, Testis

MBS657371-5x1mg 5x1mg
EUR 2835

Tissue, Total Protein, Human Tumor, Thymus

MBS657475-1mg 1mg
EUR 680

Tissue, Total Protein, Human Tumor, Thymus

MBS657475-5x1mg 5x1mg
EUR 2835

Tissue, Total Protein, Human Tumor, Kidney

MBS657592-1mg 1mg
EUR 680

Tissue, Total Protein, Human Tumor, Kidney

MBS657592-5x1mg 5x1mg
EUR 2835

Total Protein - Human Tumor Tissue: Adrenal

P1235004 1 mg
EUR 542

Total Protein - Human Tumor Tissue: Bladder

P1235010 1 mg
EUR 357

Total Protein - Human Tumor Tissue: Parotid

P1235190 1 mg
EUR 542

Total Protein - Human Tumor Tissue: Pharynx

P1235199 1 mg
EUR 357

Total Protein - Human Tumor Tissue: Stomach

P1235248 1 mg
EUR 357

Total Protein - Human Tumor Tissue: Thyroid

P1235265 1 mg
EUR 357

Tissue, Total Protein, Human Tumor, Bladder

MBS657051-1mg 1mg
EUR 680

Tissue, Total Protein, Human Tumor, Bladder

MBS657051-5x1mg 5x1mg
EUR 2835

Tissue, Total Protein, Human Tumor, Adrenal

MBS657120-1mg 1mg
EUR 820

Tissue, Total Protein, Human Tumor, Adrenal

MBS657120-5x1mg 5x1mg
EUR 3470

Tissue, Total Protein, Human Tumor, Stomach

MBS657334-1mg 1mg
EUR 680

Tissue, Total Protein, Human Tumor, Stomach

MBS657334-5x1mg 5x1mg
EUR 2835

Tissue, Total Protein, Human Tumor, Parotid

MBS657391-1mg 1mg
EUR 820

Tissue, Total Protein, Human Tumor, Parotid

MBS657391-5x1mg 5x1mg
EUR 3470

Tissue, Total Protein, Human Tumor, Thyroid

MBS657476-1mg 1mg
EUR 680

Tissue, Total Protein, Human Tumor, Thyroid

MBS657476-5x1mg 5x1mg
EUR 2835

Tissue, Total Protein, Human Tumor, Pharynx

MBS657593-1mg 1mg
EUR 680

Tissue, Total Protein, Human Tumor, Pharynx

MBS657593-5x1mg 5x1mg
EUR 2835

Total Protein - Human Tumor Tissue: Prostate

P1235201 1 mg
EUR 542

Tissue, Total Protein, Human Tumor, Prostate

MBS657602-1mg 1mg
EUR 820

Tissue, Total Protein, Human Tumor, Prostate

MBS657602-5x1mg 5x1mg
EUR 3470

Total Protein - Human Tumor Tissue: Lymphoma

P1235161 1 mg
EUR 357

Total Protein - Human Tumor Tissue: Pancreas

P1235188 1 mg
EUR 542

Total Protein - Human Tumor Tissue: Melanoma

P1235218A 1 mg
EUR 542

Tissue, Total Protein, Human Tumor, Melanoma

MBS657116-1mg 1mg
EUR 820

Tissue, Total Protein, Human Tumor, Melanoma

MBS657116-5x1mg 5x1mg
EUR 3470

Tissue, Total Protein, Human Tumor, Pancreas

MBS657286-1mg 1mg
EUR 820

Tissue, Total Protein, Human Tumor, Pancreas

MBS657286-5x1mg 5x1mg
EUR 3470

Tissue, Total Protein, Human Tumor, Duodenum

MBS657482-1mg 1mg
EUR 820

Tissue, Total Protein, Human Tumor, Duodenum

MBS657482-5x1mg 5x1mg
EUR 3470

Tissue, Total Protein, Human Tumor, Lymphoma

MBS657500-1mg 1mg
EUR 680

Tissue, Total Protein, Human Tumor, Lymphoma

MBS657500-5x1mg 5x1mg
EUR 2835

Total Protein - Human Tumor Tissue: Esophagus

P1235106 1 mg
EUR 357

Tissue, Total Protein, Human Tumor, Esophagus

MBS657127-1mg 1mg
EUR 680

Tissue, Total Protein, Human Tumor, Esophagus

MBS657127-5x1mg 5x1mg
EUR 2835

Tissue, Total RNA, Human Tumor Cell Line, K 562 (Human Chronic Myelogenous Leukemia; Bone Marrow), BioGenomics

MBS638703-005mg 0.05mg
EUR 485

Tissue, Total RNA, Human Tumor Cell Line, K 562 (Human Chronic Myelogenous Leukemia; Bone Marrow), BioGenomics

MBS638703-5x005mg 5x0.05mg
EUR 1960

Total Protein - Human Tumor Tissue: Gallbladder

P1235118 1 mg
EUR 542

Total Protein - Human Tumor Tissue: Parathyroid

P1235189 1 mg
EUR 542

Tissue, Total Protein, Human Tumor, Gallbladder

MBS656963-1mg 1mg
EUR 820

Tissue, Total Protein, Human Tumor, Gallbladder

MBS656963-5x1mg 5x1mg
EUR 3470

Tissue, Total Protein, Human Tumor, Parathyroid

MBS657229-1mg 1mg
EUR 820

Tissue, Total Protein, Human Tumor, Parathyroid

MBS657229-5x1mg 5x1mg
EUR 3470

Total Protein - Human Tumor Tissue: Neurofibroma

P1235177A 1 mg
EUR 542

Total Protein - Human Tumor Tissue: Neurilemmoma

P1235177B 1 mg
EUR 542

Tissue, Total Protein, Human Tumor, Neurilemmoma

MBS657261-1mg 1mg
EUR 820

The results presented here show here that the inactivation of the Jak-Stat signaling route significantly reduces the apoptotic response induced by infection, thus facilitating the establishment and maintenance of persistent IBDV infections. Members of the Birnaviridae family, including an infectious scholarship disease virus (IBDV). , has a double behavior, causing acute infections that are often followed by the establishment of long-service life asymptomatic infections. Indeed, persistently infected specimens could act as efficient virus tanks, so potentially contributing to the diffusion of viruses. Despite the key importance of this biological trait, information on mechanisms triggering IBDV persistence is negligible.

Leave A Comment